Merck to showcase advances in the science of cancer with new data presented at ASCO 2024

Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors

Merck to acquire life science company Mirus Bio for US$ 600 million

Acquisition will advance Merck’s integrated offering for viral vector manufacturing

AstraZeneca plans $1.5 billion ADCs manufacturing facility in Singapore

Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs

Glenmark and BeiGene ink agreement for marketing and distribution of Tislelizumab and Zanubrutinib in India

MMV and GSK win Society of Chemical Industry Innovation Award

The award recognizes powerful science–industry collaborations for social good

Merck discontinues Phase 3 KeyVibe-010 trial of coformulation of Vibostolimab and Pembrolizumab

Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria

AbbVie and Gilgamesh Pharmaceuticals collaborate to develop next-gen therapies for psychiatric disorders

Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders

AstraZeneca completes equity investment agreement with Cellectis

Cellectis is also eligible to receive an investigational new drug (IND) option fee and development

Aptar Closures introduces new e-Commerce disc top closure for beauty, personal and home care applications

Aptar Closures’ E-Disc Top securely protects against in-transit leakage while eliminating the need for liners and extra shipping preparation fees

Bayer secures full ownership in Bayer Zydus Pharma by acquiring remaining 25% stake

The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market